Dare Bioscience, Inc. 8-K

What Happened
Daré Bioscience, Inc. (DARE) filed an 8-K on June 12, 2026 reporting that its stockholders approved an amendment to the Daré Bioscience, Inc. 2022 Stock Incentive Plan to increase the number of shares available for issuance under the plan by 1,500,000 shares. The board had previously approved this Amendment No. 2, which became effective upon shareholder approval. A copy of the amendment is included as an exhibit to the filing.

Key Details

• Stockholders approved a 1,500,000-share increase to the 2022 Stock Incentive Plan.
• The board of directors had pre-approved the amendment, contingent on shareholder approval.
• The company filed the definitive proxy statement related to the Meeting on April 28, 2026; the 8-K was filed June 12, 2026.
• Amendment No. 2 to the 2022 Plan is filed as Exhibit 10.1 to the 8-K.

Why It Matters
This amendment increases the pool of shares the company can grant as stock awards to employees, directors and consultants under its incentive plan. That provides Daré with additional capacity to issue equity-based compensation, which can help recruit and retain personnel but also represents potential future dilution for existing shareholders. Investors should review the filed amendment and the proxy statement for details on grant terms and any limits on dilution.